Disclosure of HIV-positive status has important implications for patient outcomes and preventing HIV transmission, but has been understudied in TB-HIV patients. We assessed disclosure patterns and correlates of non-disclosure among adult TB-HIV patients initiating ART enrolled in the START Study, a mixed-methods cluster-randomized trial conducted in Lesotho, which evaluated a combination intervention package (CIP) versus standard of care. Interviewer-administered questionnaire data were analyzed to describe patterns of disclosure. Patient-related factors were assessed for association with non-disclosure to anyone other than a health-care provider and primary partners using generalized linear mixed models. Among 371 participants, 95% had disclosed their HIV diagnosis to someone other than a health-care provider, most commonly a spouse/primary partner (76%). Age, TB knowledge, not planning to disclose TB status, greater perceived TB stigma, and CIP were associated with non-disclosure in unadjusted models (p < .1).
Introduction
Disclosure of HIV diagnosis is associated with improved antiretroviral therapy (ART) adherence, better health outcomes, and reduced risk of transmission (Chandra, Deepthivarma, Jairam, & Thomas, 2003; Ostermann et al., 2015; Patel et al., 2012; Ramadhani et al., 2007; Stirratt et al., 2006; Tam, Amzel, & Phelps, 2015; Wong et al., 2009 ). However, some individuals experience negative outcomes following disclosure, including stigma, discrimination, and rejection or violence (Greeff et al., 2008; Maman, van Rooyen, & Groves, 2014; Nachega et al., 2012) .
Co-infection with tuberculosis (TB) further complicates the disclosure process due to stigma surrounding both diseases (Daftary, 2012; Daftary & Padayatchi, 2012; Daftary, Padayatchi, & Padilla, 2007; Gebrekristos, Lurie, Mthethwa, & Karim, 2009; Gebremariam, Bjune, & Frich, 2010) . TB-HIV patients who have not disclosed their HIV status face barriers in accessing optimal care for both HIV and TB (Chileshe & Bond, 2010; Daftary & Padayatchi, 2013; Gebremariam et al., 2010) . However, HIV disclosure among TB-HIV patients has been understudied, and despite a World Health Organization (WHO) recommendation that HIV testing be offered to partners of TB-HIV patients (World Health Organization [WHO], 2012a [WHO], , 2012b , disclosure within sexual partnerships has not been widely explored. Understanding correlates of disclosure will aid in identifying individuals who may benefit from additional disclosure counseling, resulting in improved outcomes for patients and their partners.
Utilizing data from TB-HIV patients initiating ART in Lesotho, which bears one of the highest burdens of both TB and HIV in the world (Lesotho Ministry of Health and Social Welfare and ICF Macro, 2015; WHO, 2015) , we assessed patterns of disclosure of HIV status, and explored factors associated with nondisclosure to: anyone other than a health-care provider; and primary sexual partners.
Methods
The START Study was a mixed-methods cluster-randomized implementation science trial in Lesotho; study methodology has been previously described (Howard et al., 2016) . This analysis includes 191 and 180 participants from the combination intervention package (CIP) and standard of care (SOC) arms, respectively, who were enrolled in a measurement cohort and completed a baseline interviewer-administered questionnaire (Howard et al., 2016) . Inclusion criteria included: ART initiation ≤8 weeks after TB treatment initiation; age 18+; English-or Sesotho-speaking; and capable of providing written informed consent. Multi-drug-resistant TB cases were excluded.
The protocol was approved by the institutional review board at Columbia University Medical Center and Lesotho's National Health Institutional Review Board and Ethics Research Committee, and registered at Clin-icalTrials.gov (NCT01872390). All participants provided written informed consent.
The primary outcomes of this analysis were: selfreported disclosure of HIV status to someone other than a health-care provider; and disclosure to primary sexual partners. Participants who reported disclosure were asked whether they had disclosed to specific individuals, including a spouse/primary partner, parent, sibling, child, other relative, and friend.
Correlates of interest included sociodemographics, and regionally validated measures of hazardous or harmful alcohol use (AUDIT, Cronbach's alpha 0.86) (Chishinga et al., 2011 ; National Institute on Alcohol Abuse and Alcoholism; Saunders, Aasland, Babor, de la Fuente, & Grant, 1993) and depressive symptoms (PHQ-9, Cronbach's alpha 0.70) (Bhana, Rathod, Selohilwe, Kathree, & Petersen, 2015; Kroenke, Spitzer, & Williams, 2001; Monahan et al., 2009) . We also measured support network size, understanding of written health information, and socially desirable response tendency (Reynolds, 1982 ) (Cronbach's alpha 0.80). Study arm was investigated, as CIP participants may have had some exposure to the intervention, including 32 participants who enrolled after a disclosure flipchart was introduced in response to a need identified by health-care providers.
We developed TB-and HIV-related knowledge items (seven true/false questions per disease) to assess broad understanding of transmission, symptoms, and treatment; knowledge scores were included as the total number of items answered correctly. Intent to disclose TB and a perceived TB stigma scale (14 four-point Likert items, Cronbach's alpha 0.90) were included. Participants were asked if they knew of household members who were HIV-positive. Clinical variables included time since HIV diagnosis and CD4 count at ART initiation.
All analyses were conducted using SAS ® 9.4 (SAS Institute Inc., Cary, NC). Patterns of disclosure were described as proportions disclosing to specific groups. Unadjusted and adjusted associations with non-disclosure were assessed using generalized linear mixed models with a binary outcome (disclosed/not disclosed), with a random intercept for study site due to the cluster-randomized study design. Multivariable models included all correlates significant at p < .1 in the unadjusted analyses.
Results
Among 371 participants, 56% were men; median age was 35 years (interquartile range [IQR] 30-44) and 54% were married or cohabitating. The median time since HIV diagnosis was 33 days, and among 212 participants with data, the median CD4 count at ART initiation was 151 cells/μL (IQR 59-307).
Nearly all participants (n = 354, 95%) reported disclosing their HIV status to at least one person other than a health-care provider (Figure 1 ). Among those who had disclosed, the median number of people to whom participants had disclosed was 4 (IQR 2-5). Participants had most commonly disclosed to a spouse/primary partner (76%) or parent (72%).
In unadjusted analyses, greater TB knowledge (OR 0.67 per item, 95% confidence interval [CI] 0.51-0.87), planning to disclose TB status (OR 0.18, 95% CI 0.05-0.64), age (OR 1.04, 95% CI 1.00-1.09), greater perceived TB stigma (OR 1.08, 95% CI 1.00-1.18), and CIP (OR 0.38, 95% CI 0.12-1.19) were all associated with nondisclosure to someone other than a health-care provider at p < .1; the adjusted point estimates (among N = 332 with complete data) were similar to the unadjusted (Table 1) . In adjusted analyses, those with greater knowledge about TB (aOR 0.59 per item, 95% CI 0.39-0.90), and those in CIP (aOR 0.20, 95% CI 0.05-0.79) were less likely to report non-disclosure of HIV status. Planning to disclose TB status (aOR 0.24, 95% CI 0.06-1.02) was marginally associated with lower odds of reporting non-disclosure, while greater perceived TB stigma was marginally associated with greater odds of non-disclosure (OR 1.09 per point, 95% CI 1.00-1.19). Of 230 participants with a spouse/primary partner, 220 (96%) provided information about primary partner disclosure. Of these, 167 (76%) had disclosed their HIV status (Table 2 ). In unadjusted models, being female (OR 2.28, 95% CI 1.21-4.31), married status (OR 0.03, 95% CI 0.01-0.10), electricity in the home (OR 0.47, 95% CI 0.25-0.89), not knowing the primary partner's HIV status (OR 7.75, 95% CI 1.80-33.33), and greater TB knowledge (OR 0.73 per item, 95% CI 0.59-0.90) were all associated with non-disclosure at p < .1. In adjusted models, point estimates had similar interpretation; those who knew their partner was HIV-negative or did not know their partner's status had much higher odds of non-disclosure than those who knew their partner was HIV-positive (aOR 4.20 95% CI 0.93-18.91), although this association was no longer significant. Participants who were married or living with their partner were less likely (aOR 0.03, 95% CI 0.01-0.12) to report non-disclosure than those who were not married or cohabitating. Those with electricity were also less likely to report non-disclosure (aOR 0.38, 95% CI 0.17-0.85), and for each additional correct TB knowledge item, participants were less likely to report non-disclosure (aOR 0.76 per item, 95% CI 0.59-0.98). Although marginally significant, women still had over twice the odds of nondisclosure compared to men (aOR 2.11, 95% CI 0.97-4.57).
Discussion
Although disclosure has been widely studied in populations of HIV patients, this study represents one of the first investigations of HIV disclosure in TB-HIV patients. Our estimated disclosure prevalence (95%) is consistent with previous work in HIV-positive individuals (Longinetti, Santacatterina, & El-Khatib, 2014; Obermeyer, Baijal, & Pegurri, 2011) . The correlates we found support qualitative literature: considerations about TB complicate decisions about HIV disclosure (Daftary, 2012; Daftary et al., 2007; Daftary & Padayatchi, 2012) . Additional education and disclosure counseling about TB and HIV may increase disclosure, but community-based work to reduce stigma is needed, as counseling patients is likely insufficient if structural discrimination is widespread.
Nearly a quarter of our participants had not disclosed to their primary partner. This is consistent with previous reports in HIV-positive individuals (Obermeyer et al., 2011; Vu et al., 2012) , but is concerning because of missed opportunities to offer HIV testing and referral to either treatment or prevention. Our findings of strong correlates support existing literature regarding common correlates of non-disclosure to partners, including being female, not being in a steady partnership, and not knowing the partner's status (Abdool Karim et al., 2015; Daftary & Padayatchi, 2012; DiCarlo et al., 2014; Geary et al., 2014; Longinetti et al., 2014; Przybyla et al., 2013; Reda, Biadgilign, Deribe, & Deribew, 2013) .
Couples based testing has been suggested as a means to reduce gendered HIV stigma and improve rates of mutual disclosure (DiCarlo et al., 2014) . This approach is recommended by WHO, but does not commonly occur in TB clinics, where many patients are diagnosed with HIV (WHO, 2012a (WHO, , 2012b . In cases where the partner is the TB treatment supporter, TB clinic visits may provide an opportunity to engage partners in HIV testing (WHO, 2012a). However, in Lesotho, treatment supporters do not typically accompany patients to clinic visits. Our study confirms the continued need for efforts to reach partners of TB-HIV patients.
The study's limitations include its cross-sectional nature and social desirability bias that may have yielded over-reporting of HIV disclosure. However, socially desirable response tendency was not associated with reporting disclosure. In addition, because participants were enrolled at ART initiation, we likely underestimated the prevalence of non-disclosure among all TB-HIV patients in Lesotho. We did not collect data on reasons for non-disclosure or consequences of disclosure.
Our study's strengths included detailed information about disclosure, which allowed for robust description of disclosure patterns and assessment of a wide variety of correlates. The study's design ensured that disclosure counseling was provided by health-care providers, so estimates of disclosure prevalence were not affected by study-related procedures.
Conclusions
Due to the importance of HIV disclosure for patients' and partners' well-being, our results suggest that additional efforts to support disclosure, such as counseling or couple's testing with mutual disclosure, are needed for TB-HIV patients, particularly for women and those who do not know their partners' status.
